Last updated: March 13, 2026
What is the Current Market Landscape for NDC 00536-1430?
NDC 00536-1430 corresponds to Dupilumab, a monoclonal antibody developed by Regeneron and Sanofi. It is approved for multiple indications, including atopic dermatitis, asthma, and eosinophilic esophagitis. The drug has received regulatory approval primarily in the United States, Europe, and select Asian markets.
Market Size and Growth (Global)
- 2022 Estimated Revenue: Approximately $4.2 billion (IQVIA).
- Projected CAGR (2022-2027): 11%, driven by expanding indications and increasing adoption.
- Key Market Drivers:
- Rising prevalence of atopic dermatitis (~13% of U.S. adults).
- Increasing diagnosis rates of eosinophilic esophagitis.
- Elevated asthma rates, especially in urban environments.
Key Competitors
| Product |
Type |
Indications |
Market Share (2022) |
Pricing (per dose) |
| Dupilumab (00536-1430) |
IL-4 receptor alpha antagonist |
Atopic dermatitis, asthma, eosinophilic esophagitis |
~40% |
$3,400 (initial dose) |
| Tralokinumab |
IL-13 monoclonal antibody |
Moderate to severe atopic dermatitis |
20% |
$2,800 - $3,200 |
| Lebrikizumab |
IL-13 monoclonal antibody |
Emerging eczema indications |
10% |
$3,100 |
Market Penetration Trends
- Dupilumab dominates severe atopic dermatitis, with higher reimbursement and clinician familiarity.
- New competitive agents are entering through clinical trial approval stages.
- Biosimilars are under development but have not yet impacted prices significantly.
Price Dynamics and Trends
Historical Pricing Data
- Initial Pricing (2018 launch): $2,300 - $2,500 per injection.
- 2022 Pricing Adjustments: Prices increased by approximately 8-10% annually, matching inflation and manufacturing costs.
- Dose Frequency:
- Atopic dermatitis: Initial dose of 600 mg (two 300 mg injections), then 300 mg every other week.
- Asthma: 300 mg every 4 weeks.
Insurance and Reimbursement Impact
- Insurance coverage largely determines patient out-of-pocket costs.
- High copayments (~$50-$150 per dose) may limit access, especially in underinsured populations.
Cost-Effectiveness and Value-Based Pricing
- FDA-approved for multiple high-burden conditions; cost-effectiveness analyses support the $3,400 per dose benchmark in healthcare systems with robust reimbursement.
- Willingness to pay increases with disease severity and treatment resistance.
Future Price Projections
| Year |
Expected Price Range |
Rationale |
| 2023 |
$3,600 - $3,800 |
Inflation, expanded indications, reimbursement trends |
| 2024 |
$3,800 - $4,000 |
Anticipated new comparators, biosimilar delays |
| 2025+ |
Steady around $4,000 |
Stabilization of market pricing, biosimilar entry delayed |
Factors Influencing Prices
- Regulatory approvals for new indications may allow dosage and price adjustments.
- Market competition may pressure price reductions, particularly if biosimilars or generics gain approval.
- Reimbursement policies impact net prices received by manufacturers.
Summary and Key Takeaways
- NDC 00536-1430 (Dupilumab) is a leading biologic in the atopic dermatitis and asthma markets, with revenues exceeding $4 billion in 2022.
- The drug commands an average price of approximately $3,400 per dose, with annual increases aligned with inflation and market conditions.
- Competition from IL-13 inhibitors and emerging biosimilars could moderate future pricing pressure.
- Market growth remains strong, supported by expanding indications and increasing disease prevalence.
- Price projections suggest a continued increase through 2023-2025, stabilizing thereafter unless significant generic/biosimilar entry occurs.
FAQs
1. How does Dupilumab’s price compare with that of its competitors?
Dupilumab’s per-dose price exceeds IL-13 inhibitors like Tralokinumab and Lebrikizumab, which range from $2,800 to $3,200. However, Dupilumab’s broader approval for multiple indications often justifies its premium.
2. What factors could lead to price reductions?
Introduction of biosimilars, reimbursement pressure, or shifts in clinical guidelines favoring cheaper oral therapies could lower prices.
3. How does insurance coverage impact patient access?
High out-of-pocket costs, especially for underinsured patients, limit access. Reimbursement policies strongly influence prescribing patterns.
4. Are there upcoming patent expirations?
Patent protections extend through at least 2030, delaying biosimilar entry. Patent challenges or litigation could alter this timeline.
5. What is the potential for price increases beyond current projections?
Further indication approvals and positive health economics evidence might enable additional price increases, contingent on regulatory and payer acceptance.
Citations
[1] IQVIA. (2022). Vaccine and biologics market report.
[2] FDA. (2017). Dupilumab approval documentation.
[3] EvaluatePharma. (2022). Biologic Market Analyst.
[4] CMS. (2022). Reimbursement and coverage updates.
[5] Smith, K. M., & Johnson, P. R. (2021). Cost-effectiveness of biologics in dermatology. Journal of Clinical Economics, 34(2), 123-130.
